 Xofluza is now approved in the EU for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza in children aged one year and above, and in adolescents and adults Xofluza is the first influenza antiviral with a new mechanism of action in almost 20 years, stopping viral replication faster than oseltamivir Single-dose Xofluza... The post Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year an... 